Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza

The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRIS...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbott, Timothy R., Dhamdhere, Girija, Liu, Yanxia, Lin, Xueqiu, Goudy, Laine, Zeng, Leiping, Chemparathy, Augustine, Chmura, Stephen, Heaton, Nicholas S., Debs, Robert, Pande, Tara, Endy, Drew, La Russa, Marie F., Lewis, David B., Qi, Lei S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189862/
https://www.ncbi.nlm.nih.gov/pubmed/32353252
http://dx.doi.org/10.1016/j.cell.2020.04.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189862/
https://www.ncbi.nlm.nih.gov/pubmed/32353252
http://dx.doi.org/10.1016/j.cell.2020.04.020

Ejemplares similares